Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Infused with a fresh round of financing led by Boston Scientific, RenovoRx has begun a multicenter Phase 3 study of its dual-balloon infusion catheter to treat pancreatic cancer. The study will randomize therapy to either the RenovoCath System with the drug gemcitabine or to systemic chemotherapy with gemcitabine and Celgene’s drug nab-paclitaxel delivered intravenously. The goal is to extend the current standard-of-care survival period from about one year to over two years.
Start-Up Spotlight: Embolx Believes Balloon Microcatheter Occlusion Will Be A 'Breakthrough' For BPH, Cancer
Embolx is having a big year. US FDA cleared its Sniper balloon occlusion microcatheter for pressure-directed arterial embolization a few months after the UK's NICE issued recommendations supporting prostate artery embolization for lower urinary tract symptoms caused by benign prostatic hyperplasia. Now the company is focused on improving market penetration by investing in physician-education and supporting research on new applications of targeted embolization, hoping to attract commercial partners or a possible acquirer.
A UK drug-delivery firm is bringing its antimicrobial material to the global wound-care market. Pertinax Pharma, a Bristol University spin-out, is the developer of a slow-release technology that provides controlled and sustained delivery of the antiseptic chlorhexidine.
Start-Up Spotlight: Payers, Pharma Clients Bank On Prognos' Artificial Intelligence To Predict Disease
New York-based health IT company Prognos recently secured $20.5m in Series C financing to build out its artificial intelligence capabilities, which it has applied to a giant diagnostic laboratory registry containing data from some 180 million patients. Given the shift to value-based health care and the high costs of treating chronic diseases, insurers might use information from this registry to predict the likelihood of disease and reach out to members to help head off illnesses. Pharma clients, in turn, can use the data to target physicians to help them deliver effective treatments.
Check out what Saluda Medical President Dan Bournstein had to say about the firm's responsive, closed-loop spinal cord stimulation technology for which it is seeking CE mark this year and FDA approval by 2020.
Investors are betting on mitral valves as the next "big thing" in cardiology as interest in technologies to treat mitral regurgitation heat up among the big heart players. Competition among the developers of transcatheter mitral valve repair systems is intensifying as they jostle for attention, but start-up Kephalios believes the simplicity of its technology, which precisely targets repair of the defective valve, will help it stand out.
Start-Up Spotlight: Saluda Hopes To 'Evoke' From Down Under With First Closed-Loop Spine-Stim System
Aiming to improve the lives of patients living with chronic, intractable pain, Australian start-up Saluda Medical Pty Limited is the first and only neuromodulation company in the world to develop a closed-loop spinal cord stimulation system (SCS). Unlike other SCS systems marketed today, Saluda’s device, currently in clinical trials, is designed to measure the spinal cord’s response to electrical stimulation, and then respond to patient's preferred stimulation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.